Octreotide therapy for hepatocellular carcinoma: a systematic review of the evidence from randomized controlled trials.

摘要: Currently no standard treatment for patients with advanced hepatocellular carcinoma (HCC), and available literature assessing octreotide's effect on HCC reports discordant results. The primary purpose of this study was to evaluate the octreotide therapy patient survival. secondary endpoints were assess tumor response, quality life adverse effects. PUBMED, MEDLINE, OVID SPRINGER databases searched through January 2009. Randomized controlled trials that compared placebo or selected. Finally, four randomized (three which high trials) published in 1998 later a total 373 included review. Because significant clinical heterogeneity existed between trials, making meta-analysis inappropriate; only narrative systematic review performed. Of three high-quality one(126 patients) reported could improve survival patients, whereas other two(189 suggested did not have benefit HCC; moreover, none indicated has beneficial regression decrease mass. Nonetheless, serious effects these trials. In review, results from demonstrated clear patients. order detect realistic advantage, further larger well-designed multicenter will be conducted.